NO994679L - Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist - Google Patents

Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist

Info

Publication number
NO994679L
NO994679L NO994679A NO994679A NO994679L NO 994679 L NO994679 L NO 994679L NO 994679 A NO994679 A NO 994679A NO 994679 A NO994679 A NO 994679A NO 994679 L NO994679 L NO 994679L
Authority
NO
Norway
Prior art keywords
quinoline
excitatory amino
carboxylic acid
amino acid
antagonist
Prior art date
Application number
NO994679A
Other languages
English (en)
Other versions
NO994679D0 (no
Inventor
Giuseppe Alvaro
Barbara Bertani
Romano Di Fabio
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO994679D0 publication Critical patent/NO994679D0/no
Publication of NO994679L publication Critical patent/NO994679L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(+) enantiomer av E 4-(4-acetylaminofenylkarbamoylmetylen)-5,7-diklor- 1,2,3,4-tetrahydroquinolin 2-karboksylsyre og salt derav som er antagonist av eksitatoriske aminosyrer, fremgangsmåter for fremstilling derav, farmasøytiske blandinger inneholdende disse og anvendelse i legemidler er beskrevet.
NO994679A 1997-03-26 1999-09-24 Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist NO994679L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Publications (2)

Publication Number Publication Date
NO994679D0 NO994679D0 (no) 1999-09-24
NO994679L true NO994679L (no) 1999-11-24

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994679A NO994679L (no) 1997-03-26 1999-09-24 Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist

Country Status (20)

Country Link
EP (1) EP0971896A1 (no)
JP (1) JP2001518901A (no)
KR (1) KR20010005567A (no)
CN (1) CN1257482A (no)
AP (1) AP9901659A0 (no)
AU (1) AU731394B2 (no)
BR (1) BR9808424A (no)
CA (1) CA2284710A1 (no)
EA (1) EA199900755A1 (no)
GB (1) GB9706294D0 (no)
HU (1) HUP0001661A3 (no)
ID (1) ID24306A (no)
IL (1) IL131919A0 (no)
IS (1) IS5186A (no)
NO (1) NO994679L (no)
NZ (1) NZ337793A (no)
PL (1) PL335865A1 (no)
TR (1) TR199902315T2 (no)
WO (1) WO1998042673A1 (no)
YU (1) YU47699A (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
JP4360891B2 (ja) 2003-12-09 2009-11-11 アルパイン株式会社 放送受信機能を備えた電子装置およびその装置における電子番組ガイドの表示方法
NZ565080A (en) 2005-07-22 2011-03-31 Mochida Pharm Co Ltd Novel heterocyclidene acetamide derivative
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2018229744A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147732T1 (de) * 1989-03-08 1997-02-15 Merck Sharp & Dohme Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
AP876A (en) * 1995-09-29 2000-09-27 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
CA2284710A1 (en) 1998-10-01
IS5186A (is) 1999-09-17
KR20010005567A (ko) 2001-01-15
EA199900755A1 (ru) 2000-08-28
CN1257482A (zh) 2000-06-21
TR199902315T2 (xx) 2000-05-22
HUP0001661A3 (en) 2001-12-28
BR9808424A (pt) 2000-05-23
EP0971896A1 (en) 2000-01-19
AU731394B2 (en) 2001-03-29
AP9901659A0 (en) 1999-09-30
WO1998042673A1 (en) 1998-10-01
AU7209498A (en) 1998-10-20
JP2001518901A (ja) 2001-10-16
HUP0001661A2 (hu) 2000-09-28
NO994679D0 (no) 1999-09-24
GB9706294D0 (en) 1997-05-14
PL335865A1 (en) 2000-05-22
NZ337793A (en) 2001-02-23
YU47699A (sh) 2001-12-26
ID24306A (id) 2000-07-13
IL131919A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
NO20015226L (no) Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament.
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
HUP0100941A2 (hu) Kinolin, kinazolin és pirido-pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények
NO20053114L (no) Astma og allergisk inflammasjonsmodulatorer.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
HUP0004490A2 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
NO308798B1 (no) Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
WO2003020698A3 (en) Protein tyrosine kinase inhibitors
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
HUP0002084A2 (hu) Kinolin- és kinoxalinszármazékok, melyek gátolják a vérlemezke-eredetű növekedési faktort és/vagy a p56lck tirozin-kinázokat és a vegyületeket tartalmazó gyógyászati készítmények
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
CA2327029A1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
EP0394905A3 (en) Excitatory amino acid antagonists
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
FI103111B1 (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten valmistamiseksi
NO994679L (no) Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist
NO20044156L (no) Nye 1,2,3-substituerte indolizinderivater, inhibitorer av FGF`er, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme
TR199800531T1 (xx) NMDA antagonistleri olarak tetrahidrokinolinler.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
CY1106105T1 (el) Αλας μεγλουμινης ενος συγκεκριμενου κινολινοκαρβοξυλικου οξεως ενepγου επι των υποδοχεων nmda
IS2315B (is) Nýjar greinóttar setnar amínó afleiður af 3-amínó-1-fenýl-1H[1,2,4]tríasóli, aðferðir til framleiðslu á þeim og lyfjasamsetningar sem innihalda þær
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
BR9814188A (pt) "agonistas de 5-ht1f"

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application